相关实验视频
Updated: Jan 15, 2026

07:27
Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
25.1K
一个老年患者的阿米奥达龙诱导的肺毒性:一个病例报告
Bal Krishna Subedi1, Naveen Gautam2, Anuja Upadhyay1
1Department of Internal Medicine Jefferson Einstein Montgomery Hospital East Norriton Pennsylvania USA.
Clinical case reports
|October 13, 2025
概括
老年患者甚至在标准剂量下也可能出现阿米奥达龙诱导的肺毒性 (APT). 早期检测和管理,包括戒药和使用皮质类固醇,对于稳定至关重要.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿米奥达龙是一种有效的III类抗心律失常药物.
- 阿米奥达龙与显著的器官毒性有关,特别是肺部毒性.
- 老年患者可能面临更高的艾米奥达龙诱导副作用的风险.
研究的目的:
- 在老年患者中报告阿米奥达龙诱导的肺毒性病例 (APT).
- 突出早期诊断和APT管理的重要性.
- 强调需要对接受阿米奥达龙的患者进行警监测.
主要方法:
- 一个82岁的女性患者的病例报告.
- 在阿米奥达龙治疗2年后,患者出现呼吸障碍,咳和依赖氧气.
- 通过胸部CT扫描证实了诊断,并排除了其他原因.
主要成果:
- 患者患有阿米奥达龙诱导的肺毒性 (APT).
- 停用阿米奥达龙和启动皮质类固醇导致临床稳定.
- 尽管使用标准维护剂量的阿米奥达龙,但这种情况发生了.
结论:
- 阿米奥达龙诱导的肺毒性 (APT) 即使在标准治疗剂量下,也可以潜伏地表现出来.
- 高临床怀疑指数对于老年患者的早期检测是必要的.
- 积极的监测和迅速的管理对于防止严重结果至关重要.
相关概念视频
Pharmacodynamics in Geriatric Patients: Effects of Age
187
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
187
Drug Dosing: Geriatric Patients
225
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
225
Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.8K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.8K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.9K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
196
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
196

